Author details

Full Name

Megan E McNerney

Affiliation

ORCID

Career Start Year

2000

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36725889	Oncogenic RAS promotes leukemic transformation of CUX1-deficient cells.		2023
36349721	Inherited cancer predisposing mutations in patients with therapy-related myeloid neoplasms.	Br J Haematol	2023
37906947	Haploinsufficient Transcription Factors in Myeloid Neoplasms.		2023
35084368	The significance of CUX1 and chromosome 7 in myeloid malignancies.	Current Opinion in Hematology	2022
35995095	EGR1 Haploinsufficiency Confers a Fitness Advantage to Hematopoietic Stem Cells Following Chemotherapy.	Experimental Hematology	2022
35034954	CRISPR screening in human hematopoietic stem and progenitor cells reveals an enrichment for tumor suppressor genes within chromosome 7 commonly deleted regions.	Leukemia	2022
34997000	Genomic studies controvert the existence of the CUX1 p75 isoform.	Scientific Reports	2022
34473231	Loss of a 7q gene, CUX1, disrupts epigenetically driven DNA repair and drives therapy-related myeloid neoplasms.	Blood	2021
34707089	Venetoclax imparts distinct cell death sensitivity and adaptivity patterns in T cells.	Cell Death and Disease	2021
32924016	Cytotoxic Therapy-Induced Effects on Both Hematopoietic and Marrow Stromal Cells Promotes Therapy-Related Myeloid Neoplasms.		2020
32074275	A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia.	Blood Adv	2020
29592892	Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS.	Blood	2018
30388419	The Harmful Consequences of Increased Fitness in Hematopoietic Stem Cells.		2018
29698836	System for Informatics in the Molecular Pathology Laboratory: An Open-Source End-to-End Solution for Next-Generation Sequencing Clinical Data Management.	J Mol Diagn	2018
27836695	Clinical Validation of a Next-Generation Sequencing Genomic Oncology Panel via Cross-Platform Benchmarking against Established Amplicon Sequencing Assays.	J Mol Diagn	2017
28369554	The haploinsufficient tumor suppressor, CUX1, acts as an analog transcriptional regulator that controls target genes through distal enhancers that loop to target promoters.	Nucleic Acids Research	2017
28835720	Therapy-related myeloid neoplasms: when genetics and environment collide.	Nat Rev Cancer	2017
28263985	Robust stratification of breast cancer subtypes using differential patterns of transcript isoform expression.	PLoS Genet	2017
26944478	Retroviral insertional mutagenesis identifies the del(5q) genes, CXXC5, TIFAB and ETF1, as well as the Wnt pathway, as potential targets in del(5q) myeloid neoplasms.	Haematologica	2016
25043302	Nfkb1 is a haploinsufficient DNA damage-specific tumor suppressor.	Oncogene	2015
25822087	Cooperative loss of RAS feedback regulation drives myeloid leukemogenesis.	Nature Genetics	2015
24931631	The spectrum of somatic mutations in high-risk acute myeloid leukaemia with -7/del(7q).	British Journal of Haematology	2014
25407795	Widespread genetic epistasis among cancer genes.	Nature Communications	2014
24464852	Bionimbus: a cloud for managing, analyzing and sharing large genomics datasets.	J Am Med Inform Assoc	2014
23733505	Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation.	Cancer Discov	2013
23490885	Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA.	Oral Oncol	2013
23212519	CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia.	Blood	2013
21713073	Genetic pathways leading to therapy-related myeloid neoplasms.	Mediterranean Journal of Hematology and Infectious Diseases	2011
21421111	An integrated genomic approach to the assessment and treatment of acute myeloid leukemia.	Semin Oncol	2011
20383307	Development of warm auto- and allo-antibodies in a 3-year old boy with sickle cell haemoglobinopathy following his first transfusion of a single unit of red blood cells.	Blood Transfus	2010
27792083	Natural killer cell subsets in allograft rejection and tolerance.	Current Opinion in Organ Transplantation	2007
16468959	Role of natural killer cell subsets in cardiac allograft rejection.	Am J Transplant	2006
15905190	Requirement of homotypic NK-cell interactions through 2B4(CD244)/CD48 in the generation of NK effector functions.	Blood	2006
16323413	The CD2 family of natural killer cell receptors.	Current Topics in Microbiology and Immunology	2006
15841099	A new self: MHC-class-I-independent natural-killer-cell self-tolerance.	Nature Reviews Immunology	2005
15607804	2B4 (CD244) is a non-MHC binding receptor with multiple functions on natural killer cells and CD8+ T cells.	Molecular Immunology	2005
15870174	2B4 (CD244)-CD48 interactions provide a novel MHC class I-independent system for NK-cell self-tolerance in mice.	Blood	2005
15634901	Targeted disruption of the 2B4 gene in mice reveals an in vivo role of 2B4 (CD244) in the rejection of B16 melanoma cells.	Journal of Immunology	2005
15123744	2B4 acts as a non-major histocompatibility complex binding inhibitory receptor on mouse natural killer cells.	Journal of Experimental Medicine	2004
11086108	Regulatory defects in Cbl and mitogen-activated protein kinase (extracellular signal-related kinase) pathways cause persistent hyperexpression of CD40 ligand in human lupus T cells.	Journal of Immunology	2000